|
|
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2797-2805.
Prepublished online as a Blood First Edition Paper on December 19, 2006; DOI 10.1182/blood-2006-10-049312.
Previous Article | Table of Contents | Next Article 
GENE THERAPY
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance
Brian D. Brown1,
Giovanni Sitia2,
Andrea Annoni1,
Ehud Hauben1,
Lucia Sergi Sergi1,
Anna Zingale1,
Maria Grazia Roncarolo1,3,
Luca G. Guidotti2,4, and
Luigi Naldini1,3
1 San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Milan, Italy;
2 Immunopathogenesis of Liver Infections Unit, San Raffaele Scientific Institute, Milan, Italy;
3 Vita Salute San Raffaele University, Milan, Italy;
4 Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA
Liver gene transfer is a highly sought goal for the treatment of inherited and infectious diseases. Lentiviral vectors (LVs) have many desirable properties for hepatocyte-directed gene delivery, including the ability to integrate into nondividing cells. Unfortunately, upon systemic administration, LV transduces hepatocytes relatively inefficiently compared with nonparenchymal cells, and the duration of transgene expression is often limited by immune responses. Here, we investigated the role of innate antiviral responses in these events. We show that administration of LVs to mice triggers a rapid and transient IFN ß response. This effect was dependent on functional vector particles, and in vitro challenge of antigen-presenting cells suggested that plasmacytoid dendritic cells initiated the response. Remarkably, when LVs were administered to animals that lack the capacity to respond to IFN ß, there was a dramatic increase in hepatocyte transduction, and stable transgene expression was achieved. These findings indicate that, even in the setting of acute delivery of replication-defective vectors, IFNs effectively interfere with transduction in a cell-typespecific manner. Moreover, because disabling a single component of the innate/immune network was sufficient to establish persistent xenoantigen expression, our results raise the hope that the immunologic barriers to gene therapy are less insurmountable than expected.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Interferon limits lentiviral vectors in the liver
- Roland W. Herzog
Blood 2007 109: 2670-2671.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A.-S. Beignon, K. Mollier, C. Liard, F. Coutant, S. Munier, J. Riviere, P. Souque, and P. Charneau
Lentiviral Vector-Based Prime/Boost Vaccination against AIDS: Pilot Study Shows Protection against Simian Immunodeficiency Virus SIVmac251 Challenge in Macaques
J. Virol.,
November 1, 2009;
83(21):
10963 - 10974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. Sinn, A. C. Arias, K. A. Brogden, and P. B. McCray Jr.
Lentivirus Vector Can Be Readministered to Nasal Epithelia without Blocking Immune Responses
J. Virol.,
November 1, 2008;
82(21):
10684 - 10692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Brown, A. Cantore, A. Annoni, L. S. Sergi, A. Lombardo, P. Della Valle, A. D'Angelo, and L. Naldini
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Blood,
December 15, 2007;
110(13):
4144 - 4152.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|